|
The 2020 J.P. Morgan Healthcare Conference, one of the largest industry gatherings of the year, took place in San FranciscoArtificial intelligence and big data collection are playing a larger role in the drug development process, shaping the way precision therapies are matched to a patient and driving changes in the clinical trial process along the way, according to experts.
Many industry leaders agree that the pharmaceutical sector was slower to pick up on digital trends than others, such as banking, PricewaterhouseCoopers partners said at the J.P. Morgan Healthcare Conference in San Francisco.
"The stakes are high — we've seen what happens when a drug doesn't get approved, and when you're trying to do it in a different way, the hurdles are more immense," PwC's U.S. Pharmaceutical and Life Sciences Leader Karen Young said in an interview. "The purpose of the data is to help with innovation and to speed up the go-to-market process."
JP Morgan Healthcare Conference: Big data, AI rise in drug development
More J.P. Morgan coverage
Smaller deals to drive healthcare M&A activity in 2020, experts say
M&A volume will remain high in 2020, though the value of those deals might not reach 2019's heights, PwC financial advisers said on the first day of the 2020 J.P. Morgan Healthcare Conference.
Biopharma industry looks to M&A, oncology for 2020 growth
The J.P. Morgan Healthcare Conference kicked off Jan. 13 in San Francisco with the biopharma industry looking to innovative cancer therapies and deal-making to propel growth in the new year.
Chart of the week
Hong Kong may see healthcare listings rise in 2020 as market develops
Must read
|
The latest edition of First in Human, our early-stage research feature, explores emerging treatments for the rare diseases Friedreich's ataxia and ornithine transcarbamylase deficiency.First in Human: Rare diseases pose particular challenge in early drug research
Researchers of rare diseases face a number of challenges to develop drugs for conditions with few patients, less attention by pharmaceutical companies and complex gene mutations that are barely understood.
Cancer-focused drugmakers, private equity drive healthcare M&A surge in 2019
The sector saw $334.67 billion in deal-making activity — nearly $10 billion more than 2018. But it fell short of the highs of 2014 when the industry saw $342.27 billion in M&A transactions.
Healthcare sector continues job growth trend, with 2019 surpassing prior year
The healthcare sector added 28,100 jobs in December 2019, once again fueled by growth in ambulatory healthcare services. The sector added a total of 398,800 jobs in 2019, according to data from the Bureau of Labor Statistics.
Global healthcare IPOs dip YOY in 2019; China most active region in Q4
By the end of 2019, 178 healthcare companies worldwide had completed their IPOs, raising $21.82 billion in gross proceeds, according to data compiled by S&P Global Market Intelligence.
Judges question HHS authority to force drugmakers to disclose prices in TV ads
A three-judge panel at a federal appeals court questioned whether the authority Congress granted to the U.S. Department of Health and Human Services gave it the ability to force drugmakers to disclose their list prices in TV ads.
In other news
Hospitals back in court to challenge site-neutral Medicare payments
A coalition of hospital groups are challenging site-neutral Medicare payments in federal court. The lawsuit claims that the Centers for Medicare and Medicaid Services does not have the authority to implement the 2020 Medicare pay cut.
License to Pill: Biotech, pharma deals from Dec. 30-Jan. 10
Deals from Roche Holding AG, Merck & Co. Inc. and Bristol-Myers Squibb Co. feature in this regular rundown of pharmaceutical and biotechnology licensing deals over a two-week period.
|
The Trump administration has asked the Supreme Court toTrump wants Supreme Court to slow walk ACA suit; drug pricing proposal lingers
The Trump administration and Republican state attorneys general want the Supreme Court to wait to review a challenge to the Affordable Care Act, and Sen. Grassley may be linked to Health and Human Services' delay in issuing a proposed rule.
EU agency recommends 66 drugs in 2019, lowest in 5 years
The European Medicines Agency recommended 66 medicines for marketing authorization in 2019, its lowest total in five years, data compiled by S&P Global Market Intelligence showed.
US addiction crisis far from over: Lawmakers raise new cocaine, meth concerns
Even though opioids have been the key focus in the past few years in the nation's battle to end the U.S. addiction crisis, cocaine and methamphetamine have reemerged and are driving many of the recent overdose deaths, public health officials said.
Essential Healthcare is a weekly collection of critical developments across the pharmaceutical, biotechnology, healthcare provider, healthcare technology and medical equipment industries that draws on exclusive analysis and value-added content from the Healthcare News team at S&P Global Market Intelligence. Subscribe now to get Essential Healthcare delivered to your inbox every week.